-- 
Bioline RX Rises Most in 7 Months on U.S. Patent for BL-1020

-- B y   R o n i t   G o o d m a n
-- 
2011-04-04T14:20:07Z

-- http://www.bloomberg.com/news/2011-04-04/bioline-rx-rises-most-in-7-months-on-u-s-patent-for-bl-1020-1-.html
Bioline RX Ltd. (BLRX)  advanced the most in
almost seven months after the biopharmaceutical company said it
received a U.S. patent for BL-1020 to treat schizophrenia.  The shares climbed 6.2 percent, the biggest gain since
Sept. 6, to 2.505 shekels at 4:30 p.m. close in  Tel Aviv , giving
the Jerusalem-based company a market value of 309.6 million
shekels ($89 million).  The patent is valid until September 2022, Bioline said
today in a  statement to the Tel Aviv Stock Exchange .  To contact the reporter on this story:
Ronit Goodman in Tel Aviv at 
 rgoodman9@bloomberg.net   To contact the editors responsible for this story:
Susan Lerner at 
 slerner2@bloomberg.net ;
Claudia Maedler at 
 cmaedler@bloomberg.net  